Published in Neurotherapeutics on January 01, 2008
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol (2010) 1.78
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A (2009) 1.70
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther (2013) 1.39
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab (2012) 1.30
Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother (2009) 1.28
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci (2010) 1.14
An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy. Neurosurgery (2012) 1.14
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther (2010) 1.09
Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics (2009) 1.08
Crossing the rubicon. Nat Biotechnol (2009) 1.03
Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. J Neurosci Methods (2010) 1.02
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther (2012) 1.02
Adeno-associated virus type 6 is retrogradely transported in the non-human primate brain. Gene Ther (2013) 0.99
Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol (2008) 0.98
Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther (2010) 0.97
Regional convection-enhanced delivery of gadolinium-labeled albumin in the rat hippocampus in vivo. J Neurosci Methods (2010) 0.94
Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine (2013) 0.91
Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector. Mol Ther (2015) 0.87
Guided delivery of adeno-associated viral vectors into the primate brain. Adv Drug Deliv Rev (2011) 0.86
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model. Cancer Gene Ther (2013) 0.84
Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue. Photochem Photobiol (2013) 0.84
Dynamic contrast-enhanced MRI of Gd-albumin delivery to the rat hippocampus in vivo by convection-enhanced delivery. J Neurosci Methods (2012) 0.84
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. Mol Ther Methods Clin Dev (2014) 0.83
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery. Ann Neurosci (2012) 0.82
Gene delivery to the nervous system. Mol Ther (2008) 0.81
Charting the course across the blood-brain barrier. J Clin Invest (2010) 0.81
Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence. Neuropeptides (2011) 0.79
Axonal transport of AAV9 in nonhuman primate brain. Gene Ther (2016) 0.78
Convection-enhanced drug delivery for gliomas. Surg Neurol Int (2015) 0.78
Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response. Gene Ther (2015) 0.78
Convection Enhanced Delivery: A Comparison of infusion characteristics in ex vivo and in vivo non-human primate brain tissue. Ann Neurosci (2013) 0.77
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Rapid inverse planning for pressure-driven drug infusions in the brain. PLoS One (2013) 0.76
Promising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer. Ther Deliv (2015) 0.76
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg (2016) 0.76
Time-reversal Techniques in Ultrasound-assisted Convection-enhanced Drug Delivery to the Brain: Technology Development and In Vivo Evaluation. Proc Meet Acoust (2011) 0.75
Convection-Enhanced Delivery. Neurotherapeutics (2017) 0.75
Image-guided convection-enhanced delivery into agarose gel models of the brain. J Vis Exp (2014) 0.75
Voxelized Model of Brain Infusion That Accounts for Small Feature Fissures: Comparison With Magnetic Resonance Tracer Studies. J Biomech Eng (2016) 0.75
MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther (2017) 0.75
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Transport of molecules in the tumor interstitium: a review. Cancer Res (1987) 5.74
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Diffusion measurements in agar gel. Biochemistry (1962) 3.10
Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 2.99
Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst (1989) 2.62
Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 2.10
The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther (2006) 2.10
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res (2001) 2.06
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol (2005) 1.86
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg (1991) 1.81
Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg (2002) 1.79
Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg (2004) 1.78
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol (1999) 1.77
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery (2007) 1.74
Mechanisms of disease: the blood-brain barrier. Neurosurgery (2004) 1.72
Pharmacokinetics of the carmustine implant. Clin Pharmacokinet (2002) 1.52
Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl (2003) 1.51
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg (2007) 1.51
Lipid solubility and drug penetration of the blood brain barrier. Proc Soc Exp Biol Med (1974) 1.48
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Convection-enhanced drug delivery: increased efficacy and magnetic resonance image monitoring. Cancer Res (2005) 1.35
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg (2003) 1.30
Real-time imaging and quantification of brain delivery of liposomes. Pharm Res (2006) 1.22
Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet (2006) 1.20
Biodegradable polymer implants to treat brain tumors. J Control Release (2001) 1.17
Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat (2006) 1.11
Spatial distribution of dopamine, methotrexate and antipyrine during continuous intracerebral microperfusion. Brain Res (1985) 1.02
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw (2005) 1.01
Transport of cisplatin in rat brain following microinfusion: an analysis. J Pharm Sci (1986) 0.98
Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus (2006) 0.97
Intracerebral chemotherapy: chronic microinfusion of cisplatin. Neurosurgery (1982) 0.96
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus (2006) 0.91
Three-dimensional dose verification of the clinical application of gamma knife stereotactic radiosurgery using polymer gel and MRI. Phys Med Biol (2005) 0.86
Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol (2006) 0.85
Implantable pumps for drug delivery to the brain. J Neurooncol (1995) 0.79
Use of implantable pump systems for intraarterial, intraventricular and intratumoral treatment of malignant brain tumors. Ann N Y Acad Sci (1988) 0.78
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther (2012) 2.42
Engineering GPCR signaling pathways with RASSLs. Nat Methods (2008) 2.29
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther (2006) 1.77
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci (2005) 1.73
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther (2012) 1.70
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A (2009) 1.70
Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain (2005) 1.66
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci (2010) 1.59
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther (2012) 1.55
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther (2013) 1.52
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol Ther (2004) 1.49
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.46
Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther (2008) 1.40
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.36
Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors. Hum Gene Ther (2006) 1.34
Striatal volume differences between non-human and human primates. J Neurosci Methods (2008) 1.33
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther (2010) 1.32
Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol (2005) 1.32
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther (2010) 1.31
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol (2005) 1.29
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods (2009) 1.25
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
Real-time imaging and quantification of brain delivery of liposomes. Pharm Res (2006) 1.22
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther (2009) 1.21
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol (2005) 1.17
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods (2006) 1.17
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci (2010) 1.14
Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol (2007) 1.14
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther (2010) 1.09
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther (2014) 1.08
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus (2006) 1.06
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res (2011) 1.05
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery (2010) 1.05
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res (2006) 1.04
AAV9: over the fence and into the woods . . . Mol Ther (2011) 1.04
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. J Neurooncol (2009) 1.02
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage (2010) 1.02
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther (2012) 1.02
'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol (2009) 1.01
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg (2010) 0.99
Retrospective analysis of spinal arachnoid cysts in 14 dogs. J Vet Intern Med (2002) 0.98
Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol (2010) 0.97
Convection-enhanced delivery of liposomes to primate brain. Methods Enzymol (2009) 0.96
Magnetic resonance imaging features of canine intracranial neoplasia. Vet Radiol Ultrasound (2011) 0.96
Genome-wide association analysis identifies a mutation in the thiamine transporter 2 (SLC19A3) gene associated with Alaskan Husky encephalopathy. PLoS One (2013) 0.93
Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res (2009) 0.93
Design of an in-dwelling cannula for convection-enhanced delivery. J Neurosci Methods (2010) 0.93
T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery (2011) 0.93
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis (2011) 0.93
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol (2012) 0.92
Genome-wide association mapping in dogs enables identification of the homeobox gene, NKX2-8, as a genetic component of neural tube defects in humans. PLoS Genet (2013) 0.91
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol (2009) 0.90
Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies. Mol Ther (2015) 0.90
Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery (2008) 0.90
Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther (2012) 0.89
Gene therapy for Parkinson's disease: from non-human primates to humans. Curr Opin Mol Ther (2010) 0.88
PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates. Front Hum Neurosci (2008) 0.88
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats. Mol Ther (2005) 0.87
Ultrasound-enhanced drug transport and distribution in the brain. AAPS PharmSciTech (2010) 0.86
Advances in thin tissue Golgi-Cox impregnation: fast, reliable methods for multi-assay analyses in rodent and non-human primate brain. J Neurosci Methods (2013) 0.85
Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother (2003) 0.85
Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats. Neuromuscul Disord (2008) 0.84
Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther (2012) 0.84
Gene therapy for Parkinson's disease: where are we now and where are we going? Expert Rev Neurother (2010) 0.84
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Analysis of a simulation algorithm for direct brain drug delivery. Neuroimage (2011) 0.83
Clinical features and epidemiology of cryptococcosis in cats and dogs in California: 93 cases (1988-2010). J Am Vet Med Assoc (2011) 0.83
Clinical signs, magnetic resonance imaging features, and outcome after surgical and medical treatment of otogenic intracranial infection in 11 cats and 4 dogs. J Vet Intern Med (2006) 0.82
Anatomic compression caused by high-volume convection-enhanced delivery to the brain. Neurosurgery (2009) 0.82
Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity. J Neurochem (2005) 0.82
AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. Mol Ther (2006) 0.81
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology (2010) 0.81
Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One (2011) 0.80
Quantitative assessment of blood volume and permeability in cerebral mass lesions using dynamic contrast-enhanced computed tomography in the dog. Acad Radiol (2009) 0.79
Evaluation of squeeze-induced somnolence in neonatal foals. Am J Vet Res (2012) 0.77
Evaluation of pressure-driven brain infusions in nonhuman primates by intra-operative 7 Tesla MRI. J Magn Reson Imaging (2012) 0.77
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
Automated segmentation tool for brain infusions. PLoS One (2013) 0.77
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine (Lond) (2014) 0.76
Systemic administration of propentofylline does not attenuate morphine tolerance in non-injured rodents. Neurosci Lett (2005) 0.76
Rapid inverse planning for pressure-driven drug infusions in the brain. PLoS One (2013) 0.76
Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements. J Neurosci Methods (2010) 0.76
Magnetic resonance imaging features of intracranial granular cell tumors in six dogs. Vet Radiol Ultrasound (2013) 0.75
Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study. J Neurooncol (2012) 0.75
Development of an avian brachial plexus nerve block technique for perioperative analgesia in mallard ducks (Anas platyrhynchos). J Avian Med Surg (2010) 0.75